Question-and-Answer Session
Operator
(Operator Instructions) We will go first to Steve Harr with Morgan Stanley.
Steve Harr - Morgan Stanley
I've got a couple of questions. Michelle, I guess I'm somewhat surprised you have to pay for the re-treatment trial yourself, as we’ve been understanding that Wyeth was going to pay for the development of this drug.
What, are there any other studies that Wyeth is like you are going to have to pay for between now and registration?
Michelle Burris
Actually, Steve, I'm sorry if I left the impression that we are paying for that study. We are not paying for that study at risk. We are reimbursed by Wyeth.
Steve Harr - Morgan Stanley
That makes more sense. You are just paying for it and reimbursed. I got you. Okay.
Michelle Burris
So, what that means is that's why we have to adjust the recognition period of the $40 million upfront, because we're conducting that study.
Steve Harr - Morgan Stanley
And you will, but you will be reimbursed?
Michelle Burris
Absolutely.
Steve Harr - Morgan Stanley
And any update on 016, in terms of when we are going to see any clinical data from drug?
Peter Thompson
As noted, Steve, we have filed the IND for that. So assuming that there isn't a holdup there, we would anticipate trying to get clinical activity started probably accounting for the holidays, in the first part of next year. And as is our practice, we would be providing more details about the initial clinical experience we anticipate with that drug at that time.
Steve Harr - Morgan Stanley
Great. Thank you.
Operator
Now we'll go next to William Sargent with Banc of America Securities.
William Sargent - Banc of America Securities
Hi, thank you very much for taking my question. Michelle, I was wondering, could you tell us what the new duration of the recognition period is at this point?
Michelle Burris
The recognition period, it will be, I believe, detailed out in our 10-Q. We have currently estimated that to be a six year and three months from the time of signing. And again, that speaks of our estimate of the re-treatment and the number of re-treatments; that can, obviously, change, as can the need to evaluate that timeline going forward should we conduct additional studies, or should re-treatment be accelerated or some other events come up under our research and development agreement that we take on.
- To read the full transcript on Seeking Alpha, click here »
